Pioneering Bioelectronic Research Advances in the Fight Against Inflammatory Bowel Disease
Heather Simonsen, CEO, Boomerang Medical (Credit: Business Wire)
Boomerang Medical, Inc., a women-led bioelectronic medicine company focused on autoimmune diseases, proudly announced the completion of Stage 2 of its FDA-approved pilot study. This milestone marks a significant advance in the company’s research as it progresses towards its pivotal study.
The BOOM-IBD Clinical Trial, the first prospective, multicenter study of its kind in the United States to explore the use of a bioelectronic technology designated as a Breakthrough Device by the FDA for inflammatory bowel disease (IBD), has garnered substantial patient and physician interest.
The clinical trial has successfully enrolled patients with Crohn’s disease and ulcerative colitis–the two most common forms of IBD–at multiple locations across the United States, including renowned research institutions like Mount Sinai, Columbia Irving Medical Center, and the University of Pennsylvania. The Comprehensive Digestive Institute of Nevada enrolled the last patient in the study.
“This study represents a promising step forward in the quest for expanding the armamentarium for managing IBD. Our participation underscores our dedication to advancing patient care, and we are eager to contribute valuable insights that could advance the future management of IBD,” said Christian Stone, MD, MPH, principal investigator at the Comprehensive Digestive Institute of Nevada.
IBD stands as one of the most debilitating autoimmune diseases, affecting millions globally. Living with ulcerative colitis or Crohn’s disease impacts not just physical health but also work, relationships, and well-being. While existing therapies have made significant strides in managing IBD, the complexity of the condition means that there is always room for innovative approaches.
Heather Simonsen, CEO of Boomerang Medical, commented on the recent milestone: “Successfully completing the Stage 2 enrollment for our BOOM-IBD Clinical Trial is a significant step in our research trajectory. Our heartfelt appreciation goes to the BOOM-IBD investigational sites for their dedicated efforts in this critical research.”
Source: Company Press Release